Kymera Therapeutics, Inc. (KYMR)

Biological Products, (No Diagnostic Substances) · market cap $9.7B · as of 2026-07-12

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-11-03 (est.)

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Kymera Therapeutics (KYMR) is a clinical-stage biotech with 225 employees and a ~$9.8B market cap, trading at ~$119.35. Its lead asset KT-621 is in Phase 2 for Atopic Dermatitis, with a key data readout estimated around mid-2027. The company carries ~$144M in cash against a runway of only ~4.9 months, making near-term financing a near-certainty.

The catalyst path

2026-11-03 (est.)Earningsimp 5/10
2026-12-31 (est.)Phase 1imp 5/10
2027-06-15 (est.)Phase 2 · KT-621imp 7/10

Pipeline

Asset	Phase	Indication
KT-621	Phase 2	Atopic Dermatitis

Price & technical context

3-month

-3.0%

6-month

+29.7%

12-month

+94.6%

52-wk range

$54.66–$127.31

vs 50-day MA

-3.9%

vs 200-day MA

+18.5%

Realized vol

58.1%

Max drawdown

-59.8%

Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data

SEC filings — EDGAR filings for KYMR (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.